ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an ...

SEOUL, South Korea, Nov. 29, 2021 /PRNewswire/ -- On November 24, ST Pharm Co. Ltd., an API CDMO company in Republic of Korea, announced to build the second oligonucleotide manufacturing plant for an ...

Underneath we present a selection of stocks filtered out by our screen. Overview: ST Pharm Co., Ltd. provides custom manufacturing services for active pharmaceutical ingredients and intermediates in ...

ST Pharm has agreed a $56 million API supply deal with a US biotech for oligonucleotide therapeutics, boosting its order backlog and reflecting strong demand for advanced API manufacturing in global ...

The order performance of ST Pharm, a subsidiary of Dong-A Socio Group, is on an upward trend. Although only the first half of the year has just passed, the company is already showing results nearly ...

ST Pharm (KQ:237690) Annual Report This summary provides an overview of the most significant critical numbers from each of the ST Pharm financial reports, including the ST Pharm Co Ltd income ...

Is ST Pharm Co Ltd a Good Stock to Buy? Determining whether ST Pharm Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, ...

The contract development and manufacturing organization (CDMO) is currently one of the top three suppliers of oligonucleotide, which is used to produce nucleic acid therapeutics. With its second plant ...

Korean biotechnology firm, ST Pharm, is in talks with Moderna to produce messenger RNA (mRNA) COVID-19 vaccines, sources familiar with the matter told The Korea Times, Tuesday. “ST Pharm is in talks ...